What type of study is this?

This is a Systematic Review study (also classified as: Meta-Analysis).

September 16, 2025Open Access

All‐cause and cause‐specific mortality in people with depression: a large‐scale systematic review and meta‐analysis of relative risk and aggravating or attenuating factors, including antidepressant treatment

JCJoe Kwun Nam ChanChinese University of Hong Kong MSMarco SolmiUniversity of Ottawa HLHeidi Ka Ying LoUniversity of Connecticut

Key Points

Individuals with depression face a doubled risk of all-cause mortality compared to controls, indicating a severe public health concern.
Suicide risk among depressed individuals is particularly high, with a relative risk of nearly 10 times greater than the general population.
Antidepressant use is associated with lower all-cause mortality, demonstrating the potential for effective intervention strategies.
Early identification of high-risk subgroups, like those with treatment-resistant depression, can help in implementing targeted therapeutic approaches.

Abstract

Depression has been reported to be associated with premature mortality. However, no meta-analysis has comprehensively examined all-cause and cause-specific mortality risk in people with this condition, focusing also on possible aggravating and attenuating factors, including antidepressant treatment. We conducted a systematic review and meta-analysis of cohort studies to synthesize mortality risk estimates associated with depression (major depressive disorder and dysthymia) due to any and specific causes, and when depression is accompanied by comorbid conditions. Effects of antidepressant medication and electroconvulsive therapy (ECT), and other potential moderators of mortality risk, were evaluated. We searched EMBASE, Medline and PsycINFO databases up to January 26, 2025, pooling mortality estimates using random-effect models. Publication bias, subgroup and meta-regression analyses, and quality assessment (Newcastle-Ottawa Scale) were performed. Across 268 studies, 10,842,094 individuals with depression and 2,837,933,536 control subjects were included. All-cause mortality was doubled in people with depression versus no depression/general population controls (relative risk, RR=2.10, 95% CI: 1.87-2.35, I2=99.9%), being especially high for suicide (RR=9.89, 95% CI: 7.59-12.88, I2=99.6%), but also elevated for natural causes (RR=1.63, 95% CI: 1.51-1.75, I2=99.6%). Among individuals with versus without depression matched for comorbid conditions, the depression-associated mortality risk was also significantly elevated (RR=1.29, 95% CI: 1.21-1.37, I2=99.9%). Depression with versus without psychotic symptoms (RR=1.61, 95% CI: 1.45-1.78, I2=6.3%), and treatment-resistant versus non-treatment-resistant depression (RR=1.27, 95% CI: 1.16-1.39, I2=85.3%), conferred an incremental mortality risk. Antidepressant use (versus no antidepressant use) was associated with significantly lower all-cause mortality in people with depression (RR=0.79, 95% CI: 0.68-0.93, I2=99.2%). ECT use (versus no ECT use) was associated with reduced all-cause mortality (RR=0.73, 95% CI: 0.66-0.82, I2=0%), natural-cause mortality (RR=0.76, 95% CI: 0.59-0.97, I2=12.0%), and suicide (RR=0.67, 95% CI: 0.53-0.85, I2=32.3%). Our results affirm heightened mortality risk in depression, identify clinically relevant patient subgroups with increased mortality risk, and highlight mortality-reducing effects of antidepressant treatment and ECT. Multipronged intervention approaches targeting physical health improvement and suicide risk alleviation, optimizing antidepressant treatment, and pursuing early identification and effective interventions for psychotic and treatment-resistant depression, could help reduce this mortality gap, which is still growing.

KI fragen

Bookmark

View Full Paper